Park Avenue Securities LLC lifted its stake in Icon Plc (NASDAQ:ICLR) by 19.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,314 shares of the medical research company’s stock after buying an additional 379 shares during the period. Park Avenue Securities LLC’s holdings in Icon were worth $313,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. CWM LLC lifted its stake in shares of Icon by 211.8% in the fourth quarter. CWM LLC now owns 212 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 144 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of Icon by 75.5% in the third quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 179 shares during the period. BB&T Corp lifted its stake in shares of Icon by 7.3% in the fourth quarter. BB&T Corp now owns 4,416 shares of the medical research company’s stock valued at $571,000 after purchasing an additional 300 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in Icon by 119.7% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 419 shares in the last quarter. Finally, First National Bank of Omaha increased its holdings in Icon by 23.1% during the 3rd quarter. First National Bank of Omaha now owns 2,985 shares of the medical research company’s stock valued at $459,000 after acquiring an additional 560 shares in the last quarter. 88.70% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on the stock. UBS Group set a $136.00 target price on shares of Icon and gave the company a “sell” rating in a report on Saturday, October 27th. Zacks Investment Research downgraded shares of Icon from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. Evercore ISI upgraded shares of Icon from an “in-line” rating to an “outperform” rating in a report on Friday, October 26th. Mizuho upgraded shares of Icon from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $146.00 to $150.00 in a report on Friday, January 25th. Finally, BidaskClub downgraded shares of Icon from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 5th. Two research analysts have rated the stock with a sell rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $153.11.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/02/14/icon-plc-iclr-position-boosted-by-park-avenue-securities-llc.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More: How is a Moving Average Calculated?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.